Biorithm announced that it closed a $3.5 million Series A funding round to support its personalized, connected maternity care technology.
Adaptive Capital Partners and SEEDS Capital co-led the funding round. Cambridge, Massachusetts-based Biorithm plans to use the funds to fuel its expansion in Southeast Asia and the U.S. It also plans to use the cash infusion to advance its Femom obstetric remote monitoring solution. That includes completing clinical studies to support an FDA 510(k) premarket submission.
Biorithm aims to end preventable pregnancy complications with protocol-based remote monitoring of maternal and fetal biometrics. Femom, a patient-friendly offering, facilitates patient monitoring and accessible personalized guidance. It enables the seamless integration of predictive analytics to help clinicians identify early signs of complications.
The company already completed clinical trials in Singapore and the UK and now plans to expand to more priority markets.
“We feel a deep commitment to improving the health of expectant mothers and putting an end to preventable complications. There is a collapse of maternal care driven by socio-economic factors and limitation of current monitoring technologies in many regions across the world, and we are hard at work to solve this problem in partnership with others,” said Amrish Nair, BIorithm founder and CEO. “The investment we have received is a testament to our mission at Biorithm, and a future where every expectant mother has access to healthcare that is not only proactive but profoundly connected to her unique journey.”
